Individuals with dysglycaemic are prone to dyslipidaemia. Understanding the dyslipidaemic status of dysglycaemic individuals is essential for monitoring and early prevention. The aim was to assess the control of lipidaemia by glycaemic status in a representative adult population.
A retrospective health examination survey was performed on a sample of adults (n = 3947) in Malta in 2014–6. Sociodemographic data, biochemistry blood tests and anthropometric measurements were gathered. Statistical analysis was performed to evaluate the lipidaemic status and its control across the glycaemic spectrum (normoglycemic, impaired fasting glucose individuals, new diabetics and known diabetics).
The prevalence of uncontrolled dyslipidaemia was 7.75% (CI 95%: 6.69–8.63), among whom 6.97% (CI 95%: 6.21–7.81) were naïve dyslipidaemic. A progressive elevation in both LDL-C and total cholesterol but not triglycerides was present among uncontrolled dyslipidaemia individuals across the glycaemic spectrum. Global dyslipidaemia was present in 19.26% (CI 95%: 18.05–20.52) of the total general population and in 46.59% (CI 95%: 40.49–52.69%) of known diabetics. Most individuals irrespective of lipid status were normoglycaemic.
Dyslipidaemia occurs in the presence of insulin resistance. Dyslipidaemia predominated in the normoglycaemic state irrespective of statins use, indicating the need to manage dyslipidaemia prior to dysglycaemia.
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs. 2013;73:327–39. CrossRef
Samatha P, Venkateswarlu MSPV. Lipid profile levels in type 2 diabetes mellitus from the tribal population of Adilabad in Andhra Pradesh, India. J Clin diagnostic Res. 2012;6:590–2.
Reiner Ž, Tedeschi-Reiner E. Prevalence and types of persistent dyslipidemia in patients treated with statins. Croat Med J. 2013;54:339–45. CrossRef
Inzucchi SE, Amatruda JM. Lipid management in patients with diabetes: translating guidelines into action. Diabetes Care. 2003;26:1309–11. CrossRef
Solano MP, Goldberg RB. Lipid Management in Type 2 Diabetes. Clin Diabetes. 2006;24:27–32. CrossRef
Barrett-Connor E, Grundy SM, Holdbrook MJ. Plasma lipids and diabetes mellitus in an adult community. Am J Epidemiol. 1982;115:657–63. CrossRef
Betteridge DJ. Diabetic dyslipidaemia. Eur J Clin Investig. 1999;29(Suppl 2):12–6. CrossRef
Daniel MJ. Lipid management in patients with type 2 diabetes. Am Heal drug benefits. 2011;4:312–22.
Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. Rev Port Cardiol. 2006;25:865–8.
Cholesterol Treatment Trialists’ (CTT), Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90. CrossRef
Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther. 2003;99:95–112. CrossRef
Chogtu B, Magazine R, Bairy KL. Statin use and risk of diabetes mellitus. World J Diabetes. 2015;6:352–7. CrossRef
Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering--are they clinically relevant? Eur Heart J. 2003;24:225–48. CrossRef
Cuschieri S, Vassallo J, Calleja N, Camilleri R, Borg A, Bonnici G, et al. Prevalence of obesity in Malta. Obes Sci Pract. 2016;2:466–70. CrossRef
Cuschieri S, Vassallo J, Calleja N, et al. The diabesity health economic crisis-the size of the crisis in a European island state following a cross-sectional study. Arch Public Heal. 2016;74. https://doi.org/10.1186/s13690-016-0164-6.
Cuschieri S, Malta MJ. Mediterranean diabetes hub – A journey through the years. Malta Med J. 26.
Cuschieri S, Vassallo J, Calleja N, Pace NMJ. Diabetes, pre-diabetes and their risk factors in Malta: a study profile of national cross-section prevalence study. Glob Heal Epidemiol Genomics. 2016;1. https://doi.org/10.1017/gheg.2016.18.
Hockley T, Gemmill M. European Cholesterol Guidelines Report https://policy-centre.com/wp-content/uploads/2017/04/European-Cholesterol-Guidelines07.pdf (accessed 5 November 2017).
Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23:469–80. CrossRef
American Diabetes Association. Classification and Diagnosis of Diabetes. Diabetes Care 2016; 39 Suppl 1: S13–S22.
WHO. Global action plan for the prevention and control of noncommunicable diseases 2013-2020. World Heal Organ. 2013:102.
(UK) NCGC. Statins for the primary and secondary prevention of CVD https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0071769/ (2014, accessed 6 November 2017).
Eldor R, Raz I. American Diabetes Association indications for statins in diabetes: is there evidence? Diabetes Care. 2009;32(Suppl 2):S384–91. CrossRef
Goldberg IJ. Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab. 2001;86:965–71. CrossRef
Taskinen M-R, Borén J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. 2015;239:483–95. CrossRef
Haffner SM, Mykkänen L, Festa A, et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101:975–80. CrossRef
Avramoglu RK, Basciano H, Adeli K. Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta. 2006;368:1–19. CrossRef
Buse K, Tanaka SHS. Healthy people and healthy profits? Elaborating a conceptual framework for governing the commercial determinants of non-communicable diseases and identifying options for reducing risk exposure. Glob Heal. 2017;13. https://doi.org/10.1186/s12992-017-0255-3.
Daboul MW. A study measuring the effect of high serum triglyceride and cholesterol on glucose elevation in human serum. Oman Med J. 2011;26:109–13. CrossRef
Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia. 2013;56:686–95. CrossRef
Granger BB, Bosworth HB. Medication adherence: emerging use of technology. Curr Opin Cardiol. 2011;26:279–87. CrossRef
Vanelli M, Pedan A, Liu N, Hoar J, Messier D, Kiarsis K. The role of patient inexperience in medication discontinuation: a retrospective analysis of medication nonpersistence in seven chronic illnesses. Clin Ther. 2009;31:2628–52. CrossRef
Zullig L, Gellad W, Moaddeb J, et al. Improving diabetes medication adherence: successful, scalable interventions. Patient Prefer Adherence. 2015;9:139. CrossRef
American Diabetes Association AD. 4. Lifestyle Management. Diabetes Care. 2017;40:S33–43. CrossRef
Thunander Sundbom L, Bingefors K. Women and men report different behaviours in, and reasons for medication non-adherence: a nationwide Swedish survey. Pharm Pract (Granada). 2012;10:207–21. CrossRef
Chen S-L, Lee W-L, Liang T, Liao IC. Factors associated with gender differences in medication adherence: a longitudinal study. J Adv Nurs. 2014;70:2031–40. CrossRef
- The interaction of dyslipidaemia with glycaemia in an adult population study
- Springer International Publishing
Journal of Diabetes & Metabolic Disorders
Elektronische ISSN: 2251-6581
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II